Broadly Neutralizing Antibodies for HIV Eradication

doi:10.1007/s11904-016-0299-7

Review

. 2016 Feb;13(1):31-7.

doi: 10.1007/s11904-016-0299-7.

Broadly Neutralizing Antibodies for HIV Eradication

Kathryn E Stephenson^{1

2}, Dan H Barouch^{3

4}

Affiliations

¹ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA.
² Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
³ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA. dbarouch@bidmc.harvard.edu.
⁴ Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA. dbarouch@bidmc.harvard.edu.

PMID: 26841901
PMCID: PMC4779134
DOI: 10.1007/s11904-016-0299-7

Review

Broadly Neutralizing Antibodies for HIV Eradication

Kathryn E Stephenson et al. Curr HIV/AIDS Rep. 2016 Feb.

. 2016 Feb;13(1):31-7.

doi: 10.1007/s11904-016-0299-7.

Authors

Kathryn E Stephenson^{1

2}, Dan H Barouch^{3

4}

Affiliations

¹ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA.
² Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
³ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA. dbarouch@bidmc.harvard.edu.
⁴ Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA. dbarouch@bidmc.harvard.edu.

PMID: 26841901
PMCID: PMC4779134
DOI: 10.1007/s11904-016-0299-7

Abstract

Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.

Keywords: Antibody; Broadly neutralizing antibodies; Eradication; HIV; HIV pathogenesis; HIV/AIDS; Reservoir; Review; bNAb.

PubMed Disclaimer

Cited by

Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.
Alam M, Kuwata T, Shimura K, Yokoyama M, Ramirez Valdez KP, Tanaka K, Maruta Y, Oishi S, Fujii N, Sato H, Matsuoka M, Matsushita S. Alam M, et al. Retrovirology. 2016 Sep 27;13(1):70. doi: 10.1186/s12977-016-0304-7. Retrovirology. 2016. PMID: 27670680 Free PMC article.
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Günthard HF, et al. JAMA. 2016 Jul 12;316(2):191-210. doi: 10.1001/jama.2016.8900. JAMA. 2016. PMID: 27404187 Free PMC article.
Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions.
Carravilla P, Chojnacki J, Rujas E, Insausti S, Largo E, Waithe D, Apellaniz B, Sicard T, Julien JP, Eggeling C, Nieva JL. Carravilla P, et al. Nat Commun. 2019 Jan 8;10(1):78. doi: 10.1038/s41467-018-07962-9. Nat Commun. 2019. PMID: 30622256 Free PMC article.
Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production.
O'Rourke SM, Byrne G, Tatsuno G, Wright M, Yu B, Mesa KA, Doran RC, Alexander D, Berman PW. O'Rourke SM, et al. PLoS One. 2018 Aug 2;13(8):e0197656. doi: 10.1371/journal.pone.0197656. eCollection 2018. PLoS One. 2018. PMID: 30071025 Free PMC article.
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.
Mahomed S, Garrett N, Capparelli E, Baxter C, Zuma NY, Gengiah T, Archary D, Moore P, Samsunder N, Barouch DH, Mascola J, Ledgerwood J, Morris L, Abdool Karim S. Mahomed S, et al. BMJ Open. 2019 Jul 3;9(7):e030283. doi: 10.1136/bmjopen-2019-030283. BMJ Open. 2019. PMID: 31272988 Free PMC article.

See all "Cited by" articles

References

1. UNAIDS. The Gap Report. (2014).
1. Centers for Disease Control and Prevention. HIV Surveillance Report. (2014).
1. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183–186. doi: 10.1126/science.1225416. - DOI - PMC - PubMed
1. Ledgerwood JE, et al. Safety, pharmacokinetics, and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 - PMC - PubMed
1. Caskey M, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–491. doi: 10.1038/nature14411. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] UNAIDS. The Gap Report. (2014).

[2] UNAIDS. The Gap Report. (2014).

[3] Centers for Disease Control and Prevention. HIV Surveillance Report. (2014).

[4] Centers for Disease Control and Prevention. HIV Surveillance Report. (2014).

[5] Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183–186. doi: 10.1126/science.1225416. - DOI - PMC - PubMed

[6] Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183–186. doi: 10.1126/science.1225416. - DOI - PMC - PubMed

[7] Ledgerwood JE, et al. Safety, pharmacokinetics, and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 - PMC - PubMed

[8] Ledgerwood JE, et al. Safety, pharmacokinetics, and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 - PMC - PubMed

[9] Caskey M, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–491. doi: 10.1038/nature14411. - DOI - PMC - PubMed

[10] Caskey M, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–491. doi: 10.1038/nature14411. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Broadly Neutralizing Antibodies for HIV Eradication

Affiliations

Broadly Neutralizing Antibodies for HIV Eradication

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials